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Commercialization of Biotechnology 
DANIEL G. MILLER 
Daniel Miller is the Laboratory Manager for Biotechnology at 3M 
The question of how a specific scientific advance finds its 
way into a commercial product is at least as murky as any other 
issue addresed at this conference. Additionally, in the case of 
biotechnology, where a series of related advances is creating 
an entire new industry, the problem becomes incredibly 
complex as well. 
The nature of this process, the identity and roles of the key 
participants, and the obstacles impeding progress are poorly 
understood. This misunderstanding extends not only to the 
general public, who expect to benefit from public support of 
biotechnology through the availability of biotech-derived 
products, but also to the investment, research, and surpris-
ingly, the business communities. This lack of understanding is 
all the more striking, when one realizes that each of these 
groups expects to benefit from the economic consequences 
of the successful development of this industry. 
Because of its inherent complexity, commercialization of 
biotechnology is a process that can only be conducted by 
large teams of individual specialists. The motivation for pull-
ing together such teams and financing them for the length of 
time needed to generate the anticipated products is largely 
economic. Is the size of the market for biotechnology pro-
ducts worth the investment? Finally, we need to look at the key 
issues that will limit the success ofbiotechnology, particularly 
in the United States. 
For the purposes of this analysis, we will restrict our atten-
tion to healthcare, which will limit the complexity of the 
issues involved at least to some extent. This is not to say that 
the other application areas of biotechnology are less impor-
tant or that they have a more limited market impact. However, 
of the cumulative investment in biotechnology through 1986, 
75% has gone into healthcare. Of the remainder, 18% of the 
investment has been in agriculture with just 4% going to 
chemical processing. 
The key to the commercial introduction of any new tech-
nology is the identification of a customer who can benefit 
from the products resulting from the technology. Without this 
fit between products and market on one hand and technology 
on the other, the process of commercialization does not 
produce the expected stream of new products based on the 
technology. The principal characteristics of high technology 
businesses are unique products, high risk of failure , and the 
anticipation of a correspondingly high reward. These are not 
the characteristics of businesses where several manufacturers 
supply functionally equivalent products or of businesses 
where the customer has a desire but not a need for the 
product. 
The major participants in a high-tech industry are 1) the 
university, 2) commercial research and development (which 
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can be either a small start-up company or the research and 
development lab of an established one, and 3) an organiza-
tion that provides the manufacturing, marketing, sales, and 
distribution functions required by an ongoing business. Each 
of these participants has its own source of resources and is 
rewarded in a particular way. 
The university is responsible for fundamental research in a 
scientific area and for the training of new scientists, techni-
cians, and teachers. It is funded with public money (taxes), 
which is provided as a consequence of the traditional public 
responsibility for education and the pursuit of new knowl-
edge. The research conducted at this level is not goal oriented 
(e.g., a home test for strep throat) although there may be a 
mission associated with the program (e.g., the study of infec-
tious diseases of the respiratory system). In healthcare, much 
of the funding comes from two federal agencies, the National 
Institutes of Health (NIH) and the National Science Founda-
tion (NSF) with basic biomedical research funding exceeding 
$1 billion annually. These resources are allocated by a process 
known as "peer review" where teams of academic experts 
assess the scientific merits of investigator-initiated research 
proposals and award funds on a competitive basis. On the 
whole, this system has worked remarkably well for more than 
30 years. 
Industrial research and development is a highly directed, 
goal-oriented operation with specific product development 
objectives. This work, whether it occurs in a new company or 
an established one, is intended to answer questions such as: is 
the proposed product useful?; does it work?; how should it be 
manufactured?; and, for healthcare, can it meet requirements 
of safety and efficacy established by the Food and Drug 
Administration (FDA) and related healthcare regulatory agen-
cies? Funding for this level of technology transfer comes from 
a number of sources, most of which are various forms of 
venture capital investment. In general, product development 
is considerably more expensive than the basic research that 
spawns it. 
At the third corner of the technology transfer triangle are the 
conventional business functions of manufacturing, marketing, 
sales, and distribution. These operations insure that the pro-
duct is available in a reliable form at an acceptable price to the 
right customer. They are funded by the proceeds received 
from the sale of the product and must be efficient enough to 
generate a profit, which is used for repaying investors, creating 
new jobs, and paying taxes (part of which are used to support 
the university, thereby regenerating the basic research com-
munity). 
Healthcare products resulting from biotechnology have 
certain investment profiles that are relatively predictable. A 
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• 110s1 le test based on a monoclonal antibody may take 10
��pie one year_to tu�n into a product at a co�t of $1 mil(ion. �nTlparison, a b1olog1cal replacement matenal such as msulm1 dJab tics or human growth hormone for hypopituitary
�r
,:i
rfisrn or a recombinant DNA vaccine such as hepatitis B,
J\�1 take up to five years and cost between $10 million and $20�UliOll to develop through the FDA approval process. Finally,Ille\\' therapeutic agents derived from biotechnology will fre-n eiidY take more than $50 million in cumulative investmentqiid, 10 years to reach the marketplace. While these are only-JO roximate numbers, the differences between the three
��aifons in investment levels and time are significant witht
w
, if any, shortcuts available to the product development
it:l:0;1herrnore, because of the time and investment required,
�oh of these product areas creates certain demands on theanlzation attempting to commercialize in that segment.
fOr example, a small organization is required in the diagnostic,e:i and it has to remain stably committed to the task for only a
iefatively brief time before investors are rewarded by market
entr}', Increasingly larger, more stable (and more bureau­Cfllllc) organizations are required for pharmaceutical devel­
opment, which need to maintain a high level of activity over a
period of years. Very frequently, few of the scientists and
business people involved at the onset of the program are stillii able by the time the product is ready for the marketplace. If, in light of these considerations, we look at the biotech­
nology marketplace, we find that the largest number of new
11oducrs are in the medical diagnostics area ($400 million in1986 sales), the next largest are the biological replacement�re.duct ($100 million in sales) and the new therapeutic
1gencs have not yet appeared in the marketplace, althoughbrge numbers are entering the clinical trial stage. 
Through the first quarter of 1987, more than $6 billion has
been invested in biotechnology companies in the United
Slate by venture capitalists and other private investors. Cur­
reruly, this investment has a valuation in the stock markets of
ipproximately $10 billion, nearly one-third of which is embo­
died in one company, Genentech. In addition to this invest­
ment, more than 50 companies in the Fortune 500 have
lnltlar d some form of internal investment in biotechnology
programs. While the extent of this investment is harder to
e.stlmate accurately because many of these companies have
not commented publicly, based on information that is in the
public domain, a $1 billion annual expenditure has been
imated by the NSF. 
What products are all of these dollars chasing? Most esti­mates of the diagnostic markets for biotechnology are in the11 billion dollar range by 1992. The estimates for the biologi­�I replacement products are similar. Clearly, in identified
Pmduct areas, it is likely that the financial returns on anindu try-wide basis will not justify the investment. What thenare the prospects? Biotechnology is a revolution in applied biology, which has�en described in terms of operations such as cloning and�ltpresslng genes or the construction of hybridomas. While1his is true, the full picture is much more exciting. Biotech­nology represents the change of biology from a descriptive or
elllpirical science with little or no theory to one firmly rooted1� the physical sciences of chemistry and physics. When11ewed in this way, biotechnology becomes not just the ability
Ill Olake an enzyme or a peptide hormone, it becomes a new'/fay of thinking. 
,searching for a reasonable parallel, one quickly comes up Wtth the changes in the electronics industry since the discov-
ery of the transistor. The scientists at the time knew that they
had a practical replacement for the vacuum tube but they did
not foresee, in 1950, the pocket calculators or personal com­
puters of the 1980s or many of the other things that semicon­
ductors make possible. 
Similarly, those of us involved in biotechnology can see
clearly the possibility of producing, at economical prices,
authentic human insulin or growth hormone. What we can
only dimly forecast are the effects of chemical biology on
procedures to design and synthesize pharmaceuticals and
agrichemicals that are more effective and less toxic. The rapid
pace of change in biotechnology shortens our forward vision
from years to months and even weeks as results of basic and
applied research from all over the globe pour forth. It is
extremely difficult to predict the direction and outcome of
research based on the tools now being applied to problems in
neurology, rheumatology, and cancer. It is in this turbulent
environment that investment decisions are being made, set­
ting up the commercial organizations to pursue markets and
products that are yet to be identified. 
Even with the increasing unpredictability of the specific
direction of biotechnology, it is becoming apparent that fore­
casts made just a few years ago of $20-$50 billion in
biotechnology-derived products by the year 2000 are looking
more achievable. More than 200 diagnostic tests with an
annual market value of $400 million have been approved by
the FDA and introduced in the past five years. In the United
States, FDA approval and market introduction of six biological
products have been achieved. Just one of these biologicals,
human growth hormone, reached $50 million in 1986 sales for
the treatment of one form of dwarfism. If this agent can be
shown to be effective in other clinical situations, such as
wound healing, this number would increase substantially. 
What are the constraints that must be overcome in order to
accomplish these goals? The larger scientific teams and longer
timelines characteristic of biotechnology, represent a change
from what the investment community, whether public or
private, is accustomed to. An indication of this are the frequent
press releases announcing this or that breakthrough, partly in
an effort to maintain investor confidence during the long
product development cycle. This also means that investments
are larger and tied up longer than would be typical in other
high-technology situations, translating to a higher risk and
requiring a larger reward to justify the investment. 
Another hurdle is that the manufacturing technology is
relatively undeveloped for biotechnology, particularly in the
United States. This means that scale-up problems occur fre­
quently, causing problems with profitability. Recognizing this,
a number of academic centers have been set up to address the
problems in bioprocessing technology, including one at the
University of Minnesota. 
There continue to be problems with patent protection in
biotechnology; the U.S. Patent and Trademark Office is strug­
gling with policies and procedures in this area that will have to
be worked out in the courts eventually. The federal regulat01y
policy concerning biotechnology is in serious disarray in spite
of nearly 10 years of work at various levels. This makes it more
difficult for commercial organizations to comply with regula­
tions in a responsible and reliable way. 
These last two issues, more than any others, increase therisk that a given biotechnology development effort co-qld fail
for arbitrary and capricious reasons unrelated to the success or
failure of the technology itself. 
Finally, at least three issues need to receive attention if
effective biotechnology public policy is to be established.
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First, biotechnology, like any other rapidly developing techni-
cal area, requires a strong academic base for both training and 
research purposes. The current system of funding by NIH and 
NSF based on peer review of research proposals, has worked 
well at the national level in research universities and should 
be continued. However, problems remain in areas such as the 
academic preparation of high school students in basic disci-
plines such as math, science, reading and communications 
skills, problems which are the province of state and local 
administration. 
Second, it must be recognized that while the United States • 
leads in many areas of high technology, including the princi-
pal components of biotechnology, our ability to successfully 
commercialize that technology is under tremendous competi-
tive pressure from Europe and japan. Much has recently been 
written about the death of the competitive spirit in America. 
This debate misses the point. Whatever the state of the Ameri-
can competitive spitit, that spirit is very much alive and well in 
the rest of the world. This is particularly true in biotechnology, 
a technology that easily crosses borders in the form of scien-
tific publications and international technical meetings. Stu-
dents from other countries, trained in U.S. research institu-
tions, return home to work in industrial and academic 
facilities with colleagues that equal , in most respects, those in 
the United States. A sense of complacency in matters relating 
to biotechnology would certainly have the same predictable 
result for the United States economy that is currently being 
seen in the automotive and electronics industries. 
Third, we need a better informed public. In many areas of 
high technology, the United States is becoming a two-tiered 
society: the minority who know about and understand the 
technology and its implications and the rest, who don't. This 
has several undesirable consequences including the abdica-
tion of decisionmaking power to the knowledgeable minority 
leading inevitably to mistrust, overregulation, and lost oppor-
tunities. It also diminishes the attractiveness of a technical 
career, reducing the number of U.S. students pursuing 
advanced technical education, and forcing U.S. academic insti-
tutions to go abroad in search of adequately prepared stu-
dents .< Obviously, this accelerates the development of strong 
foreign competition in high-technology fields, including 
biotechnology. 
Biotechnology: Promise and Potential in 
Animal Healthcare 
DAVID REED 
David Reed is Director of Product Development at Molecular Genetics. 
I would like to present my views on the promise and 
potential of biotechnology as it relates to the animal health-
care industry. Using various examples, some of which are 
based on experiences at Molecular Genetics, I will attempt to 
discuss current and future barriers to commercializing bio-
technology in this area, review what progress has been made 
to date in the animal healthcare field, and briefly touch on 
some policy issues relating to the above. 
Recombinant DNA-derived bovine somatotropin (rDNA-
bGH) or growth hormone is clearly one of the most visible 
animal healthcare products to undergo commercialization. 
The promise of biotechnology for this hormone is the poten-
tial to produce huge quantities of this protein at a very eco-
nomical cost. Current estimates claim that rDNA-bGH will cost 
about five cents a dose, and that thousands of kilograms will 
be produced annually for the dairy and beef cattle markets. 
Treatment of cattle with this synthetic form of a naturally 
occurring hormone may result in a 15% increase in milk 
production and a 10 to 15% increase in feed conversion 
efficiency. These figures mean that farmers will be able to 
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produce significantly more milk and meat per animal while 
using the same, or perhaps, less feed costs resulting in 
cheaper costs of production. 
Unlike many other extravagant promises you hear from 
biotechnology advocates, the benefits of rDNA-bGH are real 
and attainable in the near term. Only a few technical barriers 
prevent rDNA-bGH from reaching the marketplace; few other 
rDNA-derived proteins or substances can make that claim. 
With rDNA-bGH, the barriers to commercialization are either 
in marketing or regulatory approval. The market issues con-
cern the impact increased milk production will have on the 
price support structure within the dairy industry. There is a 
very real danger in producing 15% more milk per year without 
reducing the number of producing animals. With introduction 
of rDNA-bGH, dairy farmers will have to consider reducing the 
size of their herds so that the real benefit from using this 
hormone can be realized (i.e., reduced labor and feed costs). 
The public should not fear rDNA-bGH because of the science 
or technology involved or because milk may contain the 
hormone (native bGH has probably been in the milk you have 
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